Financial Strategy During MedTech Commercialization

The objective of the commercialization financial strategy is to secure sufficient capital to support manufacturing scale-up, sales organization development, and early adoption without facing a liquidity crisis during the slow initial revenue ramp.

Commercialization is typically the most capital-intensive phase for a medical device company. The product is technically de-risked after FDA clearance, but the business risk increases because the company must now build manufacturing capacity, establish a commercial organization, and prove market adoption.

Major Cost Categories During Commercialization

A CFO’s commercialization financial strategy is primarily about managing burn while validating revenue traction.

The major cost categories that appear during commercialization include the following:

• Manufacturing scale-up becomes the largest operational expense. This includes contract manufacturing costs, tooling, quality systems, inventory builds, and supply chain management. Working capital requirements increase as inventory must be produced before sales occur.

• Commercial infrastructure is the second major cost category. The company must recruit and train a sales organization, build clinical support teams, and invest in marketing, physician education, and conference presence.

• Market access activities also become important, including reimbursement strategy, coding support, and health economics data.

  
  

• Regulatory and quality operations, including post-market surveillance, complaint handling, and manufacturing compliance systems. These costs tend to rise simultaneously, which increases burn before meaningful revenue appears.

The Risk Factors During Adoption

Revenue ramp should be modeled conservatively because hospital adoption is structurally slow. Even when physicians show interest, hospitals typically require clinical evaluation committees, supply chain approval, and contracting before purchasing begins. These factors create a timing mismatch between commercial investment and revenue realization. The company must therefore maintain sufficient liquidity to survive extended adoption cycles.

Clinical Credibility

Initial sites are usually clinical champions or early adopters who already participated in trials. After those sites begin using the product, additional hospitals enter the pipeline. Their physicians may need training before they adopt a new procedure, extending the timeline.

A conservative model often assumes limited procedure volumes per site in the first year and gradual expansion afterward. In practice, the revenue curve resembles an “S-curve,” where the first 12–18 months are slow and growth accelerates later once clinical credibility is established.

Hospital Purchasing Cycles

Most hospitals require capital equipment reviews, value analysis committee approval, and internal budgeting cycles before adding new devices. These processes can take six to twelve months.

Reimbursement

Reimbursement can also affect adoption if hospitals are uncertain about payment levels.

Tracking Key Indicators

Some of these might seem obvious, but it is important that they are constantly updated and available, so the leadership team can review and adapt the strategy.

• Number of active hospitals or accounts using the device. This metric shows whether the sales organization is successfully opening new sites.

• Utilization per site, which reflects whether physicians continue to use the device after initial evaluation.

• Gross margin becomes important to see whether the manufacturing model can scale economically.

• Pipeline metrics such as hospitals in evaluation, trained physicians, and procedures performed per quarter are often tracked as leading indicators of revenue growth. Burn rate relative to revenue growth is another metric to ensure the commercial model is becoming more efficient over time.

Investors prefer to see evidence that physicians are using the product repeatedly and that hospitals are expanding purchasing. If the company raised insufficient capital before launch, it may be forced to raise additional funding before adoption metrics are established, which weakens valuation and increases dilution.

That's why it is important to account for all these factors during this phase. It is common for companies to attempt to raise enough capital to fund at least 24 months of commercialization activity.